Hemangioma in Adults: What a Childhood Strawberry Mark Leaves Behind, Why the Fibrofatty Lump, Leftover Vessels, and Loose Skin Rarely Fade on Their Own, Which Lasers and Operations Treat the Residue, and How to Tell a Hemangioma From a Vascular Malformation That Behaves Differently

The story usually starts with a photograph from infancy. A small red spot appeared a week or two after birth, grew fast and bright over the next few months into a raised, strawberry-colored lump on the cheek, the lip, the nose, the scalp, or the chest, and then, slowly, over years, faded. A pediatrician told the parents it would go away by itself, and in one sense it did. The bright red is gone. What remains, thirty years later, is a soft bulge under the skin that never flattened, a faint pink or purple stain laced with fine vessels, a patch of skin that looks crinkled and thinner than the skin around it, or a lip that sits fuller on one side.

That is the residue of an infantile hemangioma, and it is far more common than the reassurance suggests. Infantile hemangiomas are the most common benign tumor of childhood, appearing in roughly 4 to 5 percent of infants, more often in girls, premature babies, low birth weight babies, and twins. The textbooks say they involute, meaning they regress. They do. But involution is not erasure, and studies that followed untreated hemangiomas into later childhood have found lasting changes in the skin in a majority of cases, with the risk highest for large, thick, and raised lesions.

This piece is written for two groups: adults living with what a childhood hemangioma left behind and wondering whether anything can be done, and parents trying to understand what the residue may look like and why early treatment now matters. It explains what a hemangioma is, what involution leaves, how the arrival of propranolol in 2008 changed the field, how lasers and surgery treat the residue in different locations, and how to tell a hemangioma from a vascular malformation, which looks similar but behaves very differently. It is general information, not a diagnosis. Any vascular mark that is changing, bleeding, or growing in an adult deserves an examination before anyone treats it as cosmetic.

What an infantile hemangioma is, and why it is not the same as a birthmark that never leaves

The short answer: an infantile hemangioma is a benign tumor of blood vessel cells that is usually absent or barely visible at birth, grows rapidly in the first months of life, and then slowly shrinks over several years, which makes it fundamentally different from a vascular malformation, a structural error in vessel formation that is present at birth and never goes away on its own.

The modern way of thinking about vascular birthmarks dates to 1982, when the surgeons John Mulliken and Julia Glowacki proposed splitting them into two groups based on their biology: tumors, which are made of proliferating cells and change over time, and malformations, which are malformed vessels that grow in proportion with the child and persist. That division is now the backbone of the classification maintained by the International Society for the Study of Vascular Anomalies (ISSVA), and it is the single most useful idea for an adult trying to understand an old mark.

Infantile hemangiomas follow a recognizable life cycle:

• Precursor. At birth there is often nothing, or only a faint pale, pink, or bruise-like patch that is easy to miss.
• Proliferation. Over the first weeks, the lesion grows quickly. Research on growth patterns, including work published in Pediatrics, found that most of the growth happens early, with the majority of final size typically reached by around three to five months of age. Superficial hemangiomas are bright red and raised; deep ones sit under the skin as a bluish swelling; many are mixed.
• Plateau and involution. Growth stops, the color dulls from red to purple to grey, and the lesion softens and shrinks. The old rule that involution proceeds at "10 percent per year" has been revised; current evidence suggests most of the shrinking that is going to happen has happened by around age four, and waiting longer rarely buys much more.

Hemangiomas are identified under the microscope by a marker called GLUT1, which infantile hemangiomas carry and other vascular lesions do not. That matters for adults because it is one of the ways a pathologist can confirm, after an excision, what an old lesion actually was. There are also rarer congenital hemangiomas, fully formed at birth, which either regress rapidly in the first year, never regress at all, or partly regress. They are GLUT1 negative and behave on their own timetable.

Two points from the pediatric side carry into adulthood. First, large segmental hemangiomas on the face, those spread over a region rather than a single spot, can be part of PHACE syndrome, which involves abnormalities of the brain, arteries, heart, and eyes. Second, hemangiomas around the eye can block vision during infancy and cause lasting amblyopia, and hemangiomas of the lip and nose are prone to ulceration and distortion. Adults who had one of these as a baby sometimes carry consequences beyond the skin, which should come up at any consultation, alongside the general advice in the piece on preoperative testing.

What involution leaves behind: the fibrofatty residue, the vessels, the scar, and the shape change

The short answer: as a hemangioma shrinks, its blood vessel cells are gradually replaced by fat and fibrous tissue, and the stretched skin over it does not always tighten, so the typical adult residue is some combination of a soft fatty bulge, leftover fine vessels, thin wrinkled skin, scarring from old ulceration, and distortion of the lip, nose, or eyelid.

The word "involution" sounds like the lesion simply disappears. In reality, the tumor undergoes a slow replacement. The vessel-forming cells die off and the space they occupied fills with a mix of fat and fibrous tissue, called fibrofatty residuum. A small, flat hemangioma may leave nothing visible. A large, thick, raised one almost always leaves something. Studies following untreated lesions have reported residual changes in somewhere between about half and two thirds of children, and the American Academy of Pediatrics, in its 2019 clinical practice guideline on infantile hemangioma, emphasized that permanent skin changes are common enough that waiting is not a neutral choice for high-risk lesions.

The residue falls into several recognizable types, and they matter because each responds to different treatment:

• Fibrofatty tissue. A soft, compressible bulge that feels like a fatty lump under normal or slightly discolored skin. It does not go away with time, laser, or creams. It responds to excision or, in some locations, liposuction.
• Telangiectasias. Fine, threadlike red or purple vessels that remain on the surface, sometimes as a faint pink stain. These respond well to vascular lasers, the same technology described in the piece on facial redness and broken capillaries.
• Atrophic or redundant skin. Skin that was stretched over a raised lesion often stays thin, crinkled, and loose once the lesion shrinks, sometimes described as looking like a deflated balloon or crepe paper. It may be paler or yellowish compared with the surrounding skin.
• Ulceration scars. Ulceration is the most common complication of infantile hemangiomas, especially on the lip, the diaper area, and skin folds. It is painful in infancy and heals with a scar, sometimes a depressed or white one, that behaves like any other scar and is treated as one, as described in the pieces on scar care after surgery and acne scar treatment.
• Structural distortion. A hemangioma growing during infancy can push neighboring tissue out of place. On the lip, it can leave the red part of the lip fuller or longer on one side and the border between lip and skin uneven. On the nose, a tip hemangioma can splay the cartilages apart and leave a broad, bulbous tip, sometimes called a Cyrano nose. Near the eye, it can leave a heavy lid or a lid that sits lower than its partner.

"Involution is not erasure. The red fades, but the fat, the loose skin, and the shape the tumor pushed the lip or nose into are still there, and they do not keep improving after early childhood."

The practical consequence is that an adult who was told to wait should stop waiting. Whatever residue is present at age ten is, for practical purposes, what will be present at forty. That is not an argument for alarm, since many people live comfortably with a faint mark, but it does mean that if the residue bothers someone, there is no medical reason to hold out for further improvement.

The propranolol era changed childhood treatment, and why adults treated before it often carry more residue

The short answer: since a chance observation in 2008, a common blood pressure drug called propranolol has become the first-line treatment for problematic infantile hemangiomas, and when started early it shrinks lesions quickly enough to prevent much of the residue that adults born before then were left with.

The discovery was accidental. In 2008, French physicians led by Christine Léauté-Labrèze reported in the New England Journal of Medicine that infants given propranolol for heart reasons saw their hemangiomas change color and soften within days. Propranolol is a beta blocker, a class of drug familiar to adults who take one for blood pressure or migraine, as discussed in the piece on blood pressure medications before cosmetic surgery. Controlled trials followed, and in 2014 the FDA approved an oral solution of propranolol, marketed as Hemangeol, specifically for proliferating infantile hemangiomas requiring systemic therapy.

Before propranolol, options for large or dangerous hemangiomas were limited and harsher: oral or injected corticosteroids, which worked modestly and carried growth and immune side effects, interferon in severe cases, early surgery, or simply waiting. The adults most likely to have significant residue now are those born before about 2010 with large lesions, which is most of the adult population with a visible childhood hemangioma.

The 2019 American Academy of Pediatrics guideline changed the advice to parents in a few concrete ways that are worth knowing for anyone with a baby who has a new lesion:

• Act early. Because most growth happens in the first months, the guideline recommends that infants with high-risk hemangiomas be evaluated by a specialist early, ideally by about one month of age. Waiting for the six-week or two-month check can mean missing the window when treatment prevents the most damage.
• High-risk lesions include those that are large, segmental, on the central face, lip, nose, or near the eye, those that threaten function or ulcerate, and those that might signal an associated syndrome.
• Propranolol is generally safe but supervised. It can lower blood sugar and heart rate in infants, so it is given with feeding and under medical guidance, and it is not something to start without a physician.
• Topical timolol, another beta blocker in gel form, is used off label for small, thin, superficial hemangiomas.

Propranolol does not eliminate residue in every child. Thick lesions may still leave some fibrofatty tissue or vessels, and lesions treated late, after much of the growth has happened, behave more like untreated ones. But the ceiling has moved. Fewer children now grow up with a large, distorting residue, and parents weighing whether to treat a lesion on the lip or nose should know that the cosmetic stakes of waiting are real.

Treating the residue as an adult: lasers, excision, and contour work by location

The short answer: leftover vessels and redness respond to pulsed dye and other vascular lasers, poor texture and thin skin respond partly to fractional resurfacing, and the fibrofatty bulge and structural distortion need surgery, with the specific operation depending on whether the residue sits on the lip, nose, eyelid, cheek, scalp, or body.

The first principle is to match the treatment to the component. Most adults have more than one type of residue, and a treatment plan that addresses only one of them, a laser for a lump, for example, will disappoint.

Lasers for vessels and color. The pulsed dye laser, at a wavelength of 595 nanometers in most current devices, targets hemoglobin in small vessels and is the standard tool for residual telangiectasias and pink staining. A course usually involves several sessions spaced weeks apart. Results on fine vessels are often good; the laser does nothing for the underlying bulk. Other vascular devices, including KTP lasers and intense pulsed light, are used for similar purposes, and the logic of which device fits which vessel is the same as described in the piece on vascular lasers for facial redness. Darker skin types need more conservative settings and an experienced operator, since the laser energy is also absorbed by pigment, which is covered in the piece on lasers for sun spots and pigmentation.

Resurfacing for texture. Fractional ablative lasers, such as fractional carbon dioxide, can improve the crinkled, atrophic texture of residual skin by stimulating new collagen. The improvement is real but usually partial, and the trade-offs between ablative and non-ablative devices are the same as for any resurfacing, discussed in the piece on ablative versus non-ablative laser resurfacing. For deep depressions from old ulceration, subcision, fat grafting, or filler can lift the scar, as with the techniques in the piece on acne scar treatment.

Surgery for bulk and loose skin. The fibrofatty residuum and redundant skin are surgical problems. The surgeon removes the excess tissue and redrapes or excises the stretched skin, aiming to place the scar in a natural line. On the body and in places where a linear scar is acceptable, a straightforward elliptical excision works, similar to the principles in the piece on cosmetic mole removal. For larger residues, excision may be staged, removing part at a time to let the skin relax between operations, or done as a circular excision with a purse-string closure that shortens the final scar. Liposuction is sometimes used to thin a fibrofatty area before or instead of excision, though fibrous tissue does not suction as easily as ordinary fat.

The operation depends heavily on location:

• Lip. The lip is one of the most common sites for problematic residue. Excess tissue can often be removed through an incision on the inside of the lip, leaving no visible scar, with the goal of matching the volume and the border to the other side. Where the vermilion border, the line between the red lip and the skin, is uneven, it has to be realigned precisely, because a mismatch of even a millimeter is visible at conversational distance. The techniques overlap with those in the pieces on lip reduction surgery and fixing uneven lips.
• Nasal tip. A tip hemangioma can leave both fibrofatty bulk and splayed cartilage. Correction typically uses an open rhinoplasty approach to remove the residue and bring the cartilages back together, which is a specialized version of the tip work described in the piece on tip plasty. The skin of a residual nasal tip is often thinner and less forgiving than normal tip skin, which affects how precise the result can be.
• Eyelid. Residue on the upper lid can cause heaviness or a lid that sits lower than the other. Correction may combine removal of excess tissue with the techniques used for drooping lids, explained in the piece on ptosis versus blepharoplasty. Anyone who had a periocular hemangioma as an infant should have an eye exam on record before lid surgery.
• Cheek and face. Excision is planned along relaxed skin tension lines where possible. Where the main problem is volume loss rather than excess, fat grafting can restore contour, with the survival caveats covered in the piece on fat graft survival biology.
• Scalp. A scalp hemangioma may leave a patch of thinned or absent hair. Excision with closure, tissue expansion for larger areas, or hair transplantation into scar can be options.
• Body. Chest, back, and limb residues are generally simpler surgically because there is more skin laxity and scars are hidden by clothing.

Most surgeons prefer to treat significant residue in children before they start school, often around ages three to five, to address the appearance before social awareness sets in. For adults, there is no time constraint. The procedure can be planned whenever the patient is ready, with the usual scar-maturation timeline of a year or more, the same as for any facial scar.

Insurance coverage for residual hemangioma surgery varies. When the residue causes a functional problem, such as a lip that does not close properly, a lid that blocks vision, or recurrent bleeding, coverage is more likely, and some states have laws requiring coverage of reconstructive surgery for congenital anomalies, particularly in children. Purely cosmetic improvement in an adult is usually self-pay. The general principles are covered in the piece on whether insurance covers plastic surgery.

When the mark is actually a vascular malformation or something else, and why that changes everything

The short answer: a vascular mark that was present at birth, grew only in proportion with the body, never shrank, and in some cases darkened, thickened, or swelled with time is almost certainly a vascular malformation rather than a hemangioma, and malformations, especially arteriovenous malformations, can be made worse by the wrong procedure.

Many adults call any vascular birthmark a hemangioma, and many older medical records did too. The terminology was used loosely for decades, and terms like "cavernous hemangioma" were applied to lesions that are now recognized as venous malformations. That loose language has real consequences, because the treatments are completely different.

The main vascular malformations an adult might mistake for an old hemangioma are:

• Capillary malformation (port-wine stain). A flat pink, red, or purple patch present at birth, which does not shrink. Over decades, port-wine stains on the face often darken and thicken, and some develop raised nodules. A port-wine stain on the forehead or upper eyelid in infancy may be linked to Sturge-Weber syndrome, which affects the brain and eye. Pulsed dye laser is the main treatment and works better the earlier it is started, though adults still benefit.
• Venous malformation. A soft, bluish, compressible swelling that fills when the area is lower than the heart, such as when bending over, and empties when raised. It may be painful, and small calcified clots called phleboliths can form inside. Treatment is usually sclerotherapy, injecting a substance that closes the vessels, sometimes followed by surgery. The distinction from leg veins is covered in the piece on spider veins and venous reflux.
• Lymphatic malformation. A cluster of fluid-filled channels that may swell with infection or injury and can look like small blisters on the skin surface.
• Arteriovenous malformation (AVM). A tangle of abnormal connections between arteries and veins that bypasses the normal capillary network. It can appear as a warm, pulsating patch that is often quiet in childhood but may enlarge during puberty, pregnancy, or after trauma. AVMs are the most dangerous malformation to treat casually: partial excision or inappropriate injection can trigger aggressive regrowth and bleeding.

The practical rules for an adult with an old vascular mark:

• Get the diagnosis first. A dermatologist or vascular anomalies specialist can usually tell the difference by history and examination. Ultrasound with Doppler, which shows blood flow, and sometimes MRI clarify the type and depth.
• Do not inject filler into or near a vascular malformation without that diagnosis. Filler around abnormal vessels carries the same risk of vascular complications discussed in the piece on filler vascular occlusion, and an AVM is the wrong place to experiment.
• Do not let anyone partially cut out a warm or pulsating lesion in an office setting. AVMs require planned treatment, often embolization by an interventional radiologist followed by complete surgical removal, ideally at a multidisciplinary vascular anomalies center.
• Hormonal changes matter. Malformations can enlarge in pregnancy or with hormonal medications, a point worth raising with any doctor prescribing them.

New vascular lesions in adulthood are a separate category. Cherry angiomas, the small bright red dots that multiply on the trunk with age, are harmless and easily treated with laser or cautery. Venous lakes, soft dark blue bumps on the lips and ears of older adults, are common and treatable. A pyogenic granuloma, a fast-growing red bump that bleeds easily, often appears after minor injury or during pregnancy and is usually removed. But two rarer lesions explain why an adult should not self-diagnose a new vascular mark as cosmetic: Kaposi sarcoma, which appears as purple patches or nodules, and angiosarcoma, an aggressive cancer that often starts on the scalp or face of older adults as a spot that looks like a bruise that will not heal. A new, spreading, or bleeding vascular mark in an adult should be examined by a dermatologist and, where needed, biopsied, the same principle that guides the piece on Mohs reconstruction for facial skin cancer.

When it comes to choosing who treats the residue, the answer depends on what it is. Pure vessels and color are often well handled by a dermatologist with vascular laser experience. Bulk, loose skin, and structural distortion of the lip, nose, or lid need a surgeon with specific experience in hemangioma residue, typically a plastic surgeon or facial plastic surgeon, ideally one who works with a vascular anomalies team. Credentials matter for the same reasons explained in the piece on board certifications. Before and after photographs of hemangioma cases specifically, rather than general cosmetic work, are the most useful thing to ask for, with the caveats in the piece on before and after photo consent.

The honest summary

An infantile hemangioma is a benign tumor that grows fast in the first months of life and then slowly shrinks, and for many people that is the end of the story. But for a large share, especially those born before propranolol became standard and those whose lesions were large, thick, or on the lip, nose, or eyelid, involution left something behind. The typical residue is a mix of soft fibrofatty tissue, fine leftover vessels, thin crinkled skin, scarring from old ulceration, and sometimes a change in the shape of a facial feature. Most of the shrinking that is going to happen has happened by early childhood. An adult who was told to wait has waited long enough.

The residue can be treated, but only by matching the method to the component. Vascular lasers handle redness and fine vessels. Fractional resurfacing improves texture partly. Surgery handles the bulk, the loose skin, and the structural distortion, and the specific operation on the lip, nose tip, or eyelid is precise work that rewards a surgeon with specific experience in hemangioma residue. Insurance is more likely to help where function is affected.

The most important step is the first one: confirming what the mark actually is. A lesion that was present at birth and never shrank is probably a vascular malformation, not a hemangioma, and some malformations, arteriovenous malformations in particular, can be made worse by the wrong procedure. A new, growing, or bleeding vascular lesion in an adult needs a dermatology exam before anyone treats it as cosmetic. For parents, the lesson runs the other way: a rapidly growing hemangioma on a baby's face, especially on the lip, nose, or near the eye, warrants an early specialist visit, ideally in the first month or two, because treatment started early can prevent much of the residue that today's adults are left trying to fix.

A consultation in which nobody asks when the mark appeared, whether it shrank, or whether it has ever been imaged is a consultation worth repeating elsewhere, as the piece on getting a second consultation argues for any plan that skips the diagnostic questions. Old hemangioma residue is common, treatable, and rarely urgent. It deserves a correct diagnosis and a plan built around what is actually there.